Codipront 90ml Codeine Syrup: Effective Cough Relief
Overview
Codipront 90ml Codeine Syrup is a specially formulated syrup designed to provide symptomatic relief from acute dry, irritating coughs. It contains a potent blend of active ingredients, including codeine and phenyltoloxamine, to effectively manage cough symptoms in adults and children over 12 years of age.
Key Ingredients
Each milliliter of Codipront Syrup contains:
- Codeine-Poly (Styrene, Divinylbenzene)-Sulfonate: Equivalent to 200 mg of codeine
- Phenyltoloxamine-Poly (Styrene, Divinylbenzene)-Sulfonate: Equivalent to 66 mg of phenyltoloxamine
Additionally, each milliliter includes:
- Methyl Parahydroxybenzoate: 2.3 mg
- Propyl Parahydroxybenzoate: 1.0 mg
- Sorbitol (70% solution): 383.34 mg
- Potassium (as Potassium Chloride): 0.87 mg
- Sodium: 0.36 mg
Therapeutic Indications
Codipront is recommended for the symptomatic relief of acute dry cough. It is suitable for use in adults and children over the age of 12, helping to alleviate the discomfort associated with persistent coughing.
Dosage and Administration
The posology and duration of treatment with Codipront should be determined by a healthcare professional, based on the underlying condition and the severity of the cough. Patients are advised to follow their physician’s instructions closely regarding dosage and treatment duration.
Effects and Benefits
Codipront 90ml Codeine Syrup effectively suppresses the cough reflex, providing relief from irritating cough symptoms. The combination of codeine and phenyltoloxamine works synergistically to reduce coughing frequency and intensity, allowing for improved comfort and rest.
Conclusion
For those seeking effective management of acute dry cough, Codipront 90ml Codeine Syrup is a reliable option. Its well-balanced formulation and therapeutic benefits make it an ideal choice for alleviating cough symptoms in both adults and older children. Always consult a healthcare professional before use to ensure safe and appropriate treatment.
Reviews
There are no reviews yet.